Martin et al 1 suggest that caution should be exercised when prescribing long acting oral β
agonists to patients at risk of cardiac failure, based on results from a prescription event …

We read with interest the recent paper by Weatherall et al who presented data from a meta-
analysis of the relative safety of long-acting β-agonists (LABAs). 1 In 2008 the FDA reported …

Dransfield and colleagues1 advocate the use of b blockers even in patients admitted with
acute exacerbations of chronic obstructive pulmonary disease (COPD), but certain points …

For clinicians who treat patients with respiratory diseases, the use of β-blockers has, for a
long time, posed a dilemma because of the potential risk of bronchospasm and …

We would like to congratulate the Task Force (for the diagnosis and treatment of acute and
chronic heart failure 2008) in producing an excellent revision of the heart failure guidelines …

In the July issue of AnnalsATS, Gerald and colleagues argue that “making asthma
medications like albuterol... available for nonprescription use is more likely to benefit …

2. Rodrigo GJ, Castro-Rodriguez JA. Safety of long-acting β agonists for the treatment of
asthma: clearing the air. Thorax 2012; 67: 342–9. 3. Mann M, Chowdhury B, Sullivan E, et al …

The excessive use of β2 agonists has been associated with increased asthma mortality,
although this seems to be due to confounding by disease severity rather than direct drug …

Despite clear evidence of the effectiveness of b-blockers in the management of patients with
cardiac disease (heart failure and coronary artery disease) or arterial hypertension, use of …

The development and pharmacological application of beta-1 (β1)-adrenoreceptor
antagonists (beta-blockers) has been recognized as one of the most significant therapeutic …